Analysis of Long-term (Investment) Activity Ratios
Activity ratios measure how efficiently a company performs day-to-day tasks, such us the collection of receivables and management of inventory.
Long-term Activity Ratios (Summary)
Regeneron Pharmaceuticals Inc., long-term (investment) activity ratios
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).
| Long-term activity ratio | Description | The company |
|---|---|---|
| Net fixed asset turnover | An activity ratio calculated as total revenue divided by net fixed assets. | Regeneron Pharmaceuticals Inc. net fixed asset turnover ratio deteriorated from 2022 to 2023 and from 2023 to 2024. |
| Net fixed asset turnover (including operating lease, right-of-use asset) | An activity ratio calculated as total revenue divided by net fixed assets (including operating lease, right-of-use asset). | Regeneron Pharmaceuticals Inc. net fixed asset turnover ratio (with operating lease, right-of-use asset) deteriorated from 2022 to 2023 and from 2023 to 2024. |
| Total asset turnover | An activity ratio calculated as total revenue divided by total assets. | Regeneron Pharmaceuticals Inc. total asset turnover ratio deteriorated from 2022 to 2023 and from 2023 to 2024. |
| Equity turnover | An activity ratio calculated as total revenue divided by shareholders’ equity. | Regeneron Pharmaceuticals Inc. equity turnover ratio deteriorated from 2022 to 2023 and from 2023 to 2024. |
Net Fixed Asset Turnover
Regeneron Pharmaceuticals Inc., net fixed asset turnover calculation, comparison to benchmarks
| Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in thousands) | ||||||
| Revenues | 14,202,000) | 13,117,200) | 12,172,900) | 16,071,700) | 8,497,100) | |
| Property, plant, and equipment, net | 4,599,700) | 4,146,400) | 3,763,000) | 3,482,200) | 3,221,600) | |
| Long-term Activity Ratio | ||||||
| Net fixed asset turnover1 | 3.09 | 3.16 | 3.23 | 4.62 | 2.64 | |
| Benchmarks | ||||||
| Net Fixed Asset Turnover, Competitors2 | ||||||
| AbbVie Inc. | 10.97 | 10.89 | 11.76 | 11.00 | 8.73 | |
| Amgen Inc. | 4.89 | 4.53 | 4.57 | 4.69 | 4.96 | |
| Bristol-Myers Squibb Co. | — | 6.77 | 7.38 | 7.67 | 7.22 | |
| Danaher Corp. | 4.78 | 5.25 | 7.96 | 7.77 | 6.83 | |
| Eli Lilly & Co. | 2.63 | 2.64 | 2.81 | 3.15 | 2.83 | |
| Gilead Sciences Inc. | — | 5.07 | 4.93 | 5.27 | 4.90 | |
| Johnson & Johnson | 4.33 | 4.28 | 4.79 | 4.95 | 4.40 | |
| Merck & Co. Inc. | — | 2.61 | 2.77 | 2.53 | 2.67 | |
| Pfizer Inc. | — | 3.09 | 6.17 | 5.46 | 3.01 | |
| Thermo Fisher Scientific Inc. | 4.61 | 4.54 | 4.84 | 4.71 | 5.45 | |
| Vertex Pharmaceuticals Inc. | — | 8.51 | 8.06 | 6.92 | 6.47 | |
| Net Fixed Asset Turnover, Sector | ||||||
| Pharmaceuticals, Biotechnology & Life Sciences | — | 4.11 | 4.98 | 4.97 | 4.30 | |
| Net Fixed Asset Turnover, Industry | ||||||
| Health Care | — | 9.75 | 10.24 | 10.03 | 9.23 | |
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).
1 2024 Calculation
Net fixed asset turnover = Revenues ÷ Property, plant, and equipment, net
= 14,202,000 ÷ 4,599,700 = 3.09
2 Click competitor name to see calculations.
| Long-term activity ratio | Description | The company |
|---|---|---|
| Net fixed asset turnover | An activity ratio calculated as total revenue divided by net fixed assets. | Regeneron Pharmaceuticals Inc. net fixed asset turnover ratio deteriorated from 2022 to 2023 and from 2023 to 2024. |
Net Fixed Asset Turnover (including Operating Lease, Right-of-Use Asset)
Regeneron Pharmaceuticals Inc., net fixed asset turnover (including operating lease, right-of-use asset) calculation, comparison to benchmarks
| Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in thousands) | ||||||
| Revenues | 14,202,000) | 13,117,200) | 12,172,900) | 16,071,700) | 8,497,100) | |
| Property, plant, and equipment, net | 4,599,700) | 4,146,400) | 3,763,000) | 3,482,200) | 3,221,600) | |
| Operating lease right-of-use assets (included in Other noncurrent assets) | 217,400) | 78,000) | 71,200) | 71,200) | 71,200) | |
| Property, plant, and equipment, net (including operating lease, right-of-use asset) | 4,817,100) | 4,224,400) | 3,834,200) | 3,553,400) | 3,292,800) | |
| Long-term Activity Ratio | ||||||
| Net fixed asset turnover (including operating lease, right-of-use asset)1 | 2.95 | 3.11 | 3.17 | 4.52 | 2.58 | |
| Benchmarks | ||||||
| Net Fixed Asset Turnover (including Operating Lease, Right-of-Use Asset), Competitors2 | ||||||
| AbbVie Inc. | 9.62 | 9.47 | 10.24 | 9.57 | 7.46 | |
| Amgen Inc. | 4.51 | 4.08 | 4.13 | 4.23 | 4.58 | |
| Bristol-Myers Squibb Co. | — | 5.60 | 6.18 | 6.66 | 6.30 | |
| Danaher Corp. | 3.93 | 4.26 | 6.35 | 6.10 | 5.30 | |
| Eli Lilly & Co. | 2.48 | 2.45 | 2.63 | 2.93 | 2.63 | |
| Gilead Sciences Inc. | — | 4.57 | 4.51 | 4.77 | 4.34 | |
| Johnson & Johnson | 4.11 | 4.07 | 4.54 | 4.72 | 4.18 | |
| Merck & Co. Inc. | — | 2.45 | 2.60 | 2.33 | 2.43 | |
| Pfizer Inc. | — | 2.68 | 5.20 | 4.59 | 2.74 | |
| Thermo Fisher Scientific Inc. | 3.97 | 3.89 | 4.13 | 3.98 | 4.82 | |
| Vertex Pharmaceuticals Inc. | — | 6.79 | 6.13 | 5.32 | 4.83 | |
| Net Fixed Asset Turnover (including Operating Lease, Right-of-Use Asset), Sector | ||||||
| Pharmaceuticals, Biotechnology & Life Sciences | — | 3.71 | 4.47 | 4.45 | 3.90 | |
| Net Fixed Asset Turnover (including Operating Lease, Right-of-Use Asset), Industry | ||||||
| Health Care | — | 7.96 | 8.24 | 7.94 | 7.23 | |
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).
1 2024 Calculation
Net fixed asset turnover (including operating lease, right-of-use asset) = Revenues ÷ Property, plant, and equipment, net (including operating lease, right-of-use asset)
= 14,202,000 ÷ 4,817,100 = 2.95
2 Click competitor name to see calculations.
| Long-term activity ratio | Description | The company |
|---|---|---|
| Net fixed asset turnover (including operating lease, right-of-use asset) | An activity ratio calculated as total revenue divided by net fixed assets (including operating lease, right-of-use asset). | Regeneron Pharmaceuticals Inc. net fixed asset turnover ratio (with operating lease, right-of-use asset) deteriorated from 2022 to 2023 and from 2023 to 2024. |
Total Asset Turnover
Regeneron Pharmaceuticals Inc., total asset turnover calculation, comparison to benchmarks
| Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in thousands) | ||||||
| Revenues | 14,202,000) | 13,117,200) | 12,172,900) | 16,071,700) | 8,497,100) | |
| Total assets | 37,759,400) | 33,080,200) | 29,214,500) | 25,434,800) | 17,163,300) | |
| Long-term Activity Ratio | ||||||
| Total asset turnover1 | 0.38 | 0.40 | 0.42 | 0.63 | 0.50 | |
| Benchmarks | ||||||
| Total Asset Turnover, Competitors2 | ||||||
| AbbVie Inc. | 0.42 | 0.40 | 0.42 | 0.38 | 0.30 | |
| Amgen Inc. | 0.35 | 0.28 | 0.38 | 0.40 | 0.39 | |
| Bristol-Myers Squibb Co. | — | 0.47 | 0.48 | 0.42 | 0.36 | |
| Danaher Corp. | 0.31 | 0.28 | 0.37 | 0.35 | 0.29 | |
| Eli Lilly & Co. | 0.57 | 0.53 | 0.58 | 0.58 | 0.53 | |
| Gilead Sciences Inc. | — | 0.43 | 0.43 | 0.40 | 0.36 | |
| Johnson & Johnson | 0.49 | 0.51 | 0.51 | 0.52 | 0.47 | |
| Merck & Co. Inc. | — | 0.56 | 0.54 | 0.46 | 0.52 | |
| Pfizer Inc. | — | 0.26 | 0.51 | 0.45 | 0.27 | |
| Thermo Fisher Scientific Inc. | 0.44 | 0.43 | 0.46 | 0.41 | 0.47 | |
| Vertex Pharmaceuticals Inc. | — | 0.43 | 0.49 | 0.56 | 0.53 | |
| Total Asset Turnover, Sector | ||||||
| Pharmaceuticals, Biotechnology & Life Sciences | — | 0.40 | 0.47 | 0.44 | 0.39 | |
| Total Asset Turnover, Industry | ||||||
| Health Care | — | 0.76 | 0.78 | 0.73 | 0.68 | |
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).
1 2024 Calculation
Total asset turnover = Revenues ÷ Total assets
= 14,202,000 ÷ 37,759,400 = 0.38
2 Click competitor name to see calculations.
| Long-term activity ratio | Description | The company |
|---|---|---|
| Total asset turnover | An activity ratio calculated as total revenue divided by total assets. | Regeneron Pharmaceuticals Inc. total asset turnover ratio deteriorated from 2022 to 2023 and from 2023 to 2024. |
Equity Turnover
Regeneron Pharmaceuticals Inc., equity turnover calculation, comparison to benchmarks
| Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in thousands) | ||||||
| Revenues | 14,202,000) | 13,117,200) | 12,172,900) | 16,071,700) | 8,497,100) | |
| Stockholders’ equity | 29,353,600) | 25,973,100) | 22,664,000) | 18,768,800) | 11,025,300) | |
| Long-term Activity Ratio | ||||||
| Equity turnover1 | 0.48 | 0.51 | 0.54 | 0.86 | 0.77 | |
| Benchmarks | ||||||
| Equity Turnover, Competitors2 | ||||||
| AbbVie Inc. | 16.94 | 5.24 | 3.36 | 3.65 | 3.50 | |
| Amgen Inc. | 5.45 | 4.32 | 6.77 | 3.63 | 2.58 | |
| Bristol-Myers Squibb Co. | — | 1.53 | 1.49 | 1.29 | 1.12 | |
| Danaher Corp. | 0.48 | 0.45 | 0.63 | 0.65 | 0.56 | |
| Eli Lilly & Co. | 3.17 | 3.17 | 2.68 | 3.15 | 4.35 | |
| Gilead Sciences Inc. | — | 1.18 | 1.27 | 1.28 | 1.34 | |
| Johnson & Johnson | 1.24 | 1.24 | 1.24 | 1.27 | 1.31 | |
| Merck & Co. Inc. | — | 1.60 | 1.29 | 1.28 | 1.90 | |
| Pfizer Inc. | — | 0.66 | 1.05 | 1.05 | 0.66 | |
| Thermo Fisher Scientific Inc. | 0.86 | 0.92 | 1.02 | 0.96 | 0.93 | |
| Vertex Pharmaceuticals Inc. | — | 0.56 | 0.64 | 0.75 | 0.71 | |
| Equity Turnover, Sector | ||||||
| Pharmaceuticals, Biotechnology & Life Sciences | — | 1.15 | 1.24 | 1.27 | 1.22 | |
| Equity Turnover, Industry | ||||||
| Health Care | — | 2.13 | 2.09 | 2.03 | 1.99 | |
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).
1 2024 Calculation
Equity turnover = Revenues ÷ Stockholders’ equity
= 14,202,000 ÷ 29,353,600 = 0.48
2 Click competitor name to see calculations.
| Long-term activity ratio | Description | The company |
|---|---|---|
| Equity turnover | An activity ratio calculated as total revenue divided by shareholders’ equity. | Regeneron Pharmaceuticals Inc. equity turnover ratio deteriorated from 2022 to 2023 and from 2023 to 2024. |